Compare Infosys Limited (INFY) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Eli Lilly And Co — how do they compare? Infosys Limited trades at $10.73 (market cap $41.74B), while Eli Lilly And Co trades at $1,178.99 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 24.9× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Eli Lilly And Co for 93 Days on average.
| INFY | LLY | |
|---|---|---|
Market Cap | $41.74B | $1.04T |
Volume | 31,354,285 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $20.22 | $1.28K |
52-Week Low | $10.49 | $799.57 |
Typical Hold Time | 27 Days | 93 Days |
Enterprise Value | $39.48B | $1.09T |
Dividend Yield | 4.89% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.75, up 1.9% in the last 24 hours, with a bearish technical signal from moving averages. The company reported a net income of $3.16B on $19.28B revenue for 2025, with profitability metrics like a 16.37% net margin and 32.12% ROE. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, to drive innovation. Earnings have been mixed, with beats in Q4 2025 and Q1 2026 but a miss in Q2 2026.
The outlook is cautious; while valuation ratios like a P/E of 13.21 appear reasonable and analyst consensus targets $11.48, weak IT spending and AI pricing pressure pose risks. Institutional sentiment is mixed with 35% buy ratings, but negative cash flow trends in 2026 forecast demand careful monitoring of execution against guidance.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
